Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...